search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Andre Bergman
  • Research
  • Research Groups
  • Andre Bergman
  • Our research

Our research

 

Prostate cancer

Prostate cancer is the most prevalent malignant disease in men. While localized disease can be cured, metastatic disease cannot Virtually, all metastatic prostate cancers respond to lowering serum testosterone levels. However, eventually the disease will reactivate despite ongoing testosterone suppression. Our group explores gene regulation in prostate cancer which is predominantly dictated by the androgen receptor. Moreover, prostate cancer develops through distinct stages, and there is emerging evidence that components of the tumor microenvironment play an important role in driving progression. We have a special interest in the role of the innate immune system in prostate cancer development. All our studies are aimed to better understand the mechanisms behind prostate cancer progression and sensitivity to treatments, with the ultimate goal to better understand hormonal signaling and therapy resistance in cancer. Ultimately, these new insights might contribute to more personalized treatments, the identification of novel therapeutic options and minimizing over-treatment 

Genome-wide Androgen Receptor profiling in prostate cancer

We are currently performing two Phase II clinical trials, in which patients receive AR-targeting Enzalutamide treatment in the neo-adjuvant (DARANA; Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation. NCT03297385) and metastatic (PRESTO; Predicting Response to Enzalutamide as a Second Line Treatment for Metastasized Castration Resistant Prostate Cancer Patients: a biomarker design study) setting, aimed to elucidate the cellular plasticity of AR functions in prostate cancer and treatment resistance, and to better understand the impact of DNA mutations on transcriptional regulation in cancer.

The role of the innate immune system in prostate cancer development

The innate immune system and especially its dominant representatives, the macrophages, play a pivotal role in prostate cancer development, which is reflected by a relation between disease recurrence after prostatectomy and to the abundance of macrophages in the tumor microenvironment. Macrophages are plastic cells that can exert multiple functions depending on their phenotype. Through single cell sequencing of isolated macrophages from the tumor microenvironment, we identified three different phenotypes of cancer associated macrophages. Moreover, we discovered that the androgen receptor in macrophages is functional and affect the plasticity of these cells. With that, macrophages are targeted by antihomonal manipulations. We now study the prostate cancer cell bound factors that dictate sensitivity to macrophage cell killing.

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.